Stock Taper
SCREENER COMPARE ANY 2 STOCKS
ACTU
ACTUATE THERAPEUTICS INC
NASDAQ
$1.66
▼ DOWN 2.07% (-0.04)

KEY STATISTICS

Market Cap$39.60 M
52w High$9.22
52w Low$0.90
Dividend Yield—
Frequency—
P/E-1.90
Volume231.27K
Shares Out.23.93M

COMPANY

LEADERSHIP

Daniel Schmitt
CHIEF EXECUTIVE
Daniel Schmitt

COMPENSATION 2026

Salary$570,000
Stock Awards$0
Incentive Plan Pay$0
All Other Comp.$0
Total$2,166,522

ABOUT

SECTOR
Healthcare
WENT PUBLIC
August 13, 2024
METHOD OF GOING PUBLIC
IPO
FULL TIME EMPLOYEES
12

PRICE TARGET

Target High$21.00
Target Low$21.00
Target Median$21.00
Target Consensus$21.00

UPCOMING EARNINGS

DateNov 12, 2026
DayThursday
Rev. Est.—
NOV
12
THU

PRICE

$1.66 ▼ DOWN 2.07% (−$0.04)
$1.64$1.68$1.72$1.769:30 AM10:35 AM11:40 AM12:45 PM1:49 PM2:54 PM3:59 PM1.66

About Actuate Therapeutics Inc

https://actuatetherapeutics.com ↗

Actuate Therapeutics, Inc. is a clinical-stage biotech focused on developing cancer therapies, including its lead Elraglusib GSK-3 inhibitor for pancreatic, Ewing sarcoma, melanoma, and colorectal cancers.

INDUSTRY

Biotechnology

A PRODUCT ACTUATE THERAPEUTICS INC IS KNOWN FOR

elraglusib (9-ING-41)
elraglusib (9-ING-41)

Elraglusib is a first-in-class GSK-3β inhibitor in clinical trials, including Phase 2 for metastatic pancreatic cancer, targeting difficult-to-treat cancers with an oral formulation in Phase 1/2.

ETFS HOLDING THIS STOCK

ETFS HOLDING
12
LISTED HERE
2
RANKED BY POSITION SIZE
VTS.AX
0.00% · 287.4K
IWC
0.00% · 38.7K

INSTITUTIONAL OWNERSHIP

SHARES OWNED
56.55%
HOLDERS
67
TOP 12 OF 67 · RANKED BY POSITION SIZE
Bios Capital Management, LP
10.0M sh · $61.51M
Voss Capital, LLC
1.7M sh · $4.73M
Vanguard Group Inc
529.1K sh · $3.24M
Blackrock, Inc.
432.0K sh · $2.64M
Geode Capital Management, LLC
228.3K sh · $625.63K
Connective Capital Management, LLC
113.3K sh · $310.35K
Northern Trust Corp
101.4K sh · $620.71K
Palogic Value Management, L.P.
100.0K sh · $274K
Texas Capital Bank Wealth Management Services Inc
94.6K sh · $259.18K
State Street Corp
66.0K sh · $180.92K
Abs Direct Equity Fund LLC
50.0K sh · $137K
Rock Creek Group, LP
39.3K sh · $107.58K

RATINGS SNAPSHOT

Overall rating: C-

DCFROEROAD/EP/EP/B
Discounted Cash Flow3
Return On Equity1
Return On Assets1
Debt To Equity2
Price To Earnings1
Price To Book1
Overall Score1

INSIDER TRADES

★
DIRECTOR, OFFICER: PRESIDENT, CEO AND DIRECTOR
SCHMITT DANIEL M
Sale · 272.1K shares
2026-08-14
★
DIRECTOR, OFFICER: PRESIDENT, CEO AND DIRECTOR
SCHMITT DANIEL M
Sale · 120.5K shares
2026-08-14
★
DIRECTOR, OFFICER: PRESIDENT, CEO AND DIRECTOR
SCHMITT DANIEL M
Purchase · 272.1K shares
2026-08-14
★
DIRECTOR
Zabrowski Dan
Purchase · 15.0K shares
2026-05-21

MOST RECENT ANALYST GRADES

GRADE SUMMARY
BUY 1
1 GRADES IN THE LAST 12 MONTHS
HC Wainwright & Co. BUY

SECTORS PEERS

PEERPRICE
VOR$22.65COMPARE
ALEC$2.34COMPARE
PEPG$3.08COMPARE
NKTX$2.76COMPARE
MOLN$4.50COMPARE
SPRO$1.20COMPARE
ELTX$2.84COMPARE
MCRB$5.11COMPARE